TNF Alpha Inhibitors Market By Drug Class (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab), By Pipeline Analysis, By Regions (North America, Europe, Asia Pacific, Rest of the World)-Global Forecast up to 2025

Global TNF Alpha Inhibitors Market By Drug Class (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab), By Pipeline Analysis (Phase I, Phase II, Phase III), By Regions (North America, Europe, Asia Pacific, Rest of the World): Global Forecast up to 2025

Access the PDF sample of the report @ https://www.orbisresearch.com/contacts/request-sample/3770666

This market research report includes a detailed segmentation of the global TNF alpha inhibitors market by drug class (adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab), pipeline analysis (phase I, phase II, and phase III), and regions (North America, Europe, Asia Pacific, and Rest of the World).

Overview of the Global TNF Alpha Inhibitors Market Research:
Infoholic’s market research report predicts that the global TNF alpha inhibitors market will grow at a CAGR of 3.6% during the forecast period 2019–2025. TNF inhibitors, also known as TNF blockers, anti-TNF drugs, and biologic therapies, are a cluster of medications used to treat inflammatory conditions, including rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease (Crohn’s and ulcerative colitis), and psoriasis. The drugs decrease inflammation and can stop disease development by targeting an inflammation-causing substance, tumor necrosis factor (TNF)

The market is witnessing the loss of patents in Europe for various blockbuster drugs, resulting in the emergence of biosimilars. In April 2019, Eticovo – a biosimilar from Samsung Bioepis to Amgen’s Enbrel (etanercept), received FDA approval. In November 2018, FDA approved Hyrimoz developed by Sandoz, a biosimilar to AbbVie’s blockbuster drug Humira, which will be launched in the US market by 2023. Currently, only five approved TNF inhibitors, i.e., adalimumab, certolizumab, etanercept, golimumab, and infliximab, control the market. The wide application of these drugs for numerous autoimmune diseases ensures constant growth of the market during the forecast period 2019–2025.

 

Key players operating in this field, i.e., AbbVie Inc., Amgen Inc., Johnson & Johnson, and Celgene Corporation, are generating the majority of the revenue in the global TNF alpha inhibitors market.

According to Infoholic Research analysis, North America accounted for the largest share of the global TNF alpha inhibitors market in 2018 and will retain a high position during the forecast period. North America is followed by Europe, with a market share of more than 20% in 2018.

By Drug Class:
• Adalimumab
• Certolizumab Pegol
• Etanercept
• Golimumab
• Infliximab
In 2018, the adalimumab segment accounted for the largest share and is expected to grow at a mid-single-digit CAGR during the forecast period. Increased clinical efficacy and high preference by physicians for the treatment of severe rheumatic diseases made the segment the largest shareholder in 2018. Golimumab is expected to grow at a high CAGR during the forecast period 2019–2025.

Pipeline Analysis:
• Phase I
• Phase II
• Phase III
Many companies are making huge investments to develop products and enter the market as soon as biologics lose their patents. Among various TNF alpha inhibitors, adalimumab has the highest number of ongoing clinical trials, followed by certolizumab pegol.
By Regions:
• North America
• Europe
• Asia Pacific
• Rest of the World
Based on geography, North America dominated the market in 2018 with a market share of over 60% and is expected to maintain this position during the forecast period. Europe is projected to grow at a high CAGR during the forecast period. The increasing acceptance of biosimilars and increasing investments in the R&D of new drugs make Europe the fastest-growing region during the forecast period.

Global TNF Alpha Inhibitors Market Research Competitive Analysis: The market is growing at a steady rate, i.e., at a CAGR of 3.6% during the forecast period 2019–2025. New drug launches, product approvals, strategic partnerships, and collaborations are among the significant strategies adopted by market leaders to maintain their leadership position. For instance, in July 2019, the US FDA approved HADLIMA by Samsung Bioepis, a biosimilar referencing HUMIRA, to treat juvenile idiopathic arthritis, adult Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, rheumatoid arthritis, and plaque psoriasis. In March 2019, the US FDA approved Cimzia injection to treat non-radiographic axial spondyloarthritis (nr-axSpA) in adults, with detached signs of swelling making it the first-ever FDA approved treatment fulfilling the unmet needs for nr-axSpA; and in May 2018, the drug was approved for the treatment of moderate-to-severe plaque psoriasis.

The rising incidence of chronic autoimmune diseases has led to the increasing launch of biosimilars globally. In May 2019, Fresenius Kabi launched biosimilar adalimumab IDACIO in Germany. In May 2019, Janssen launched Simponi Autoinjector in Japan, and the drugs are distributed by Mitsubishi Tanabe. In addition, other leading vendors are focusing on hugely investing in R&D activities to develop new drugs to obtain a high share in the market.
Key Vendors:
• AbbVie Inc.
• Novartis AG
• Amgen Inc.
• Johnson & Johnson
• Celgene Corporation
• Celltrion Healthcare
• Samsung Bioepis Co. Ltd.
• Apogenix
• 3SBIO Inc.
• Shanghai CP Guojian Pharmaceutical Co. Ltd.
Key Competitive Facts:
• UCB Biopharma S.P.R.L. is conducting a phase 3 clinical trial in 15 centers in Germany to study “Efficacy and safety of certolizumab pegol (CZP) versus active comparator and placebo in subjects with Plaque Psoriasis (PSO) (CIMPACT)”.

• Globally, over 95% of the clinical trials of certolizumab are conducted by UCB Pharma.
• In July 2018, Mylan made a patent license agreement with AbbVie over Mylan’s proposed Humira biosimilar. Under the terms of the agreement, AbbVie will grant Mylan exclusive licenses on Humira’s intellectual properties on July 31, 2023 in the US and other countries excluding Europe.

Benefits – The report provides complete details about the sub-segment of the global TNF alpha inhibitors market. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the pharmaceuticals segment in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.

Key Takeaways:
• Understanding the potential market opportunity with precise market size and forecast data.
• Detailed market analysis focusing on the growth of TNF alpha inhibitors industry.
• Factors influencing the growth of the TNF alpha inhibitors market.
• In-depth competitive analysis of dominant and pure-play vendors.
• Prediction analysis of the TNF alpha inhibitors industry in both developed and developing regions.
• Key insights related to major segments of the TNF alpha inhibitors market.
• Latest market trend analysis impacting the buying behavior of the consumers.

Key Stakeholders:
Browse the full report @ https://www.orbisresearch.com/reports/index/tnf-alpha-inhibitors-market-by-drug-class-adalimumab-certolizumab-pegol-etanercept-golimumab-infliximab-by-pipeline-analysis-by-regions-north-america-europe-asia-pacific-rest-of-the-world-global-forecast-up-to-2025
Table of Contents

1 Industry Outlook 10
1.1 Industry Overview 10
1.1.1 Global Driver for Pharmaceutical Demand 11
1.1.2 R&D Pipeline in Pharmaceutical Industry 11
1.1.3 Top Pharma Drugs by Sales ($Million) 11
1.2 Industry Trends 12
1.3 Total Addressable Market 13
1.4 Trends of the Immunotherapy Drugs Market 13
2 Report Outline 15
2.1 Report Scope 15
2.2 Report Summary 15
2.3 Research Methodology 16
2.4 Report Assumptions 16
3 Market Snapshot 18
3.1 Market Definition – Infoholic Research 18
3.2 Segmented Addressable Market (SAM) 18
3.3 Trends of the TNF Alpha Inhibitors Market 18
3.4 Related Markets 19
3.4.1 Oncology Drugs 19
3.4.2 Biologics 20
3.4.3 Biosimilars 20
4 Market Outlook 22
4.1 Market Segmentation 22
4.2 PEST Analysis 23
4.3 Porter 5(Five) Forces 24
5 Market Characteristics 25
5.1 DRO – Global TNF Alpha Inhibitors Market Dynamics 25
5.1.1 Drivers 25
5.1.1.1 Increasing prevalence of chronic autoimmune disease 25
5.1.1.2 Constant research to develop target-based biologics 26
5.1.2 Opportunities 26
5.1.2.1 Continuous development of biosimilars 26
5.1.2.2 Increasing opportunities in the emerging market 27
5.1.3 Restraints 27
5.1.3.1 Complex drug development process 27
5.1.3.2 Patent expiry 28
5.2 DRO – Impact Analysis 29
5.3 Key Stakeholders 30
6 Product: Market Size and Analysis 31
6.1 Overview 31
6.2 Adalimumab 32
6.3 Certolizumab Pegol 36
6.4 Etanercept 38
6.5 Golimumab 42
6.6 Infliximab 43
7 Pipeline Analysis: Market Size and Analysis 47
7.1 Overview 47
7.2 Phase I 47
7.3 Phase II 51
7.4 Phase III 54
8 Regions: Market Size and Analysis 66
8.1 Overview 66
8.2 North America 67
8.2.1 Overview 67
8.2.2 US 72
8.2.3 Canada and Others 75
8.3 Europe 77
8.3.1 Overview 77
8.3.2 UK 82
8.3.3 Germany 83
8.3.4 Russia and Ukraine 84
8.3.5 Turkey 85
8.4 Asia Pacific 86
8.4.1 Overview 86
8.4.2 India 91
8.4.3 Pakistan 92
8.4.4 Indonesia 92
8.4.5 Thailand 93
8.5 Rest of the World 93
8.5.1 Overview 93
8.5.2 Mexico 98
8.5.3 Brazil 98
8.5.4 Middle East and Africa 99
9 Competitive Landscape 100
10 Vendors Profile 102
10.1 AbbVie Inc. 102
10.1.1 Overview 102
10.1.2 Geographic Revenue 105
10.1.3 Business Focus 105
10.1.4 SWOT Analysis 106
10.1.5 Business Strategies 106
10.2 Novartis AG 107
10.2.1 Overview 107
10.2.2 Business Units 112
10.2.3 Geographic Revenue 113
10.2.4 Business Focus 113
10.2.5 SWOT Analysis 114
10.2.6 Business Strategies 114
10.3 Amgen Inc. 115
10.3.1 Overview 115
10.3.2 Geographic Revenue 120
10.3.3 Business Focus 120
10.3.4 SWOT Analysis 121
10.3.5 Business Strategies 121
10.4 Johnson & Johnson 122
10.4.1 Overview 122
10.4.2 Business Units 126
10.4.3 Geographic Revenue 127
10.4.4 Business Focus 127
10.4.5 SWOT Analysis 128
10.4.6 Business Strategies 128
10.5 Celgene Corporation 129
10.5.1 Overview 129
10.5.2 Geographic Revenue 132
10.5.3 Business Focus 132
10.5.4 SWOT Analysis 133
10.5.5 Business Strategies 133
11 Companies to Watch For 134
11.1 Apogenix 134
11.1.1 Overview 134
11.2 Celltrion Healthcare 135
11.2.1 Overview 135
11.3 Samsung Bioepis Co. Ltd. 136
11.3.1 Overview 136
11.4 3SBio Inc. 138
11.4.1 Overview 138
11.5 Shanghai CP Guojian Pharmaceutical Co. Ltd. 139
11.5.1 Overview 139
Annexure 140
Abbreviations 140

 

Direct purchase the report @ https://www.orbisresearch.com/contact/purchase-single-user/3770666

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (972)-362-8199; +91 895 659 5155

Links:
https://www.orbisresearch.com/contacts/enquiry-before-buying/3770666
https://www.orbisresearch.com/contacts/discount/3770666